Coeptis Therapeutics Inc. (OTCPK:COEP) agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. (NasdaqCM:STAB) for $6 million on April 6, 2022. The consummation of the transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a financing contingency.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.355 USD | -2.07% | -6.46% | -54.71% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
0.355 USD | -2.07% | -6.46% | 13.08M | ||
0.0007 USD | 0.00% | 0.00% | 50.81K | ||
1st Jan change | Capi. | |
---|---|---|
-54.71% | 13.08M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- COEP Stock
- News Coeptis Therapeutics Holdings, Inc.
- Coeptis Therapeutics Inc. agreed to acquire TLR5 Immunity Receptor Agnonist Platform from Statera Biopharma, Inc. for $6 million.